Does the media prefer MRVI or PRLD?

In the previous week, Prelude Therapeutics had 1 more articles in the media than Maravai LifeSciences. MarketBeat recorded 2 mentions for Prelude Therapeutics and 1 mentions for Maravai LifeSciences. Maravai LifeSciences' average media sentiment score of 1.34 beat Prelude Therapeutics' score of 0.00 indicating that Maravai LifeSciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Maravai LifeSciences 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Prelude Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is MAZE or PRLD more profitable?

Maze Therapeutics' return on equity of -36.62% beat Prelude Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Maze Therapeutics N/A -36.62% -31.78% Prelude Therapeutics N/A -118.24% -66.12%

Does the media prefer MAZE or PRLD?

In the previous week, Maze Therapeutics and Maze Therapeutics both had 2 articles in the media. Maze Therapeutics' average media sentiment score of 1.67 beat Prelude Therapeutics' score of 0.00 indicating that Maze Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Maze Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Prelude Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor PRLD or PAHC?

In the previous week, Phibro Animal Health had 1 more articles in the media than Prelude Therapeutics. MarketBeat recorded 3 mentions for Phibro Animal Health and 2 mentions for Prelude Therapeutics. Phibro Animal Health's average media sentiment score of 0.77 beat Prelude Therapeutics' score of 0.00 indicating that Phibro Animal Health is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Prelude Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Phibro Animal Health 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher earnings and valuation, AVLN or PRLD?

Avalyn Pharma has higher earnings, but lower revenue than Prelude Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Avalyn Pharma N/A N/A N/A N/A N/A Prelude Therapeutics $12.14M 28.73 -$99.50M -$1.00 N/A

Is AVLN or PRLD more profitable?

Avalyn Pharma's return on equity of 0.00% beat Prelude Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Avalyn Pharma N/A N/A N/A Prelude Therapeutics N/A -118.24% -66.12%

Does the media favor AVLN or PRLD?

In the previous week, Avalyn Pharma had 1 more articles in the media than Prelude Therapeutics. MarketBeat recorded 3 mentions for Avalyn Pharma and 2 mentions for Prelude Therapeutics. Avalyn Pharma's average media sentiment score of 0.00 equaled Prelude Therapeutics'average media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Avalyn Pharma 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Prelude Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is DMRA or PRLD more profitable?

Prelude Therapeutics' return on equity of -118.24% beat Damora Therapeutics, Inc. Common Stock's return on equity. Company Net Margins Return on Equity Return on Assets Damora Therapeutics, Inc. Common Stock N/A -428.30% -114.62% Prelude Therapeutics N/A -118.24% -66.12%

Prelude Therapeutics (PRLD) Competitors

$4.38 +0.06 (+1.39%)

As of 06/23/2026 04:00 PM Eastern

Compare

PRLD vs. MRVI, MAZE, PAHC, AVLN, and DMRA

Should you buy Prelude Therapeutics stock or one of its competitors? MarketBeat compares Prelude Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Prelude Therapeutics include Maravai LifeSciences (MRVI), Maze Therapeutics (MAZE), Phibro Animal Health (PAHC), Avalyn Pharma (AVLN), and Damora Therapeutics, Inc. Common Stock (DMRA). These companies are all part of the "pharmaceutical products" industry.

How does Prelude Therapeutics compare to Maravai LifeSciences?

Maravai LifeSciences (NASDAQ:MRVI) and Prelude Therapeutics (NASDAQ:PRLD) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, institutional ownership, valuation, dividends, earnings, media sentiment and profitability.

Maravai LifeSciences currently has a consensus target price of $5.50, suggesting a potential upside of 2.42%. Prelude Therapeutics has a consensus target price of $7.67, suggesting a potential upside of 75.04%. Given Prelude Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Prelude Therapeutics is more favorable than Maravai LifeSciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Maravai LifeSciences	2 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.20
Prelude Therapeutics	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

Prelude Therapeutics has lower revenue, but higher earnings than Maravai LifeSciences. Maravai LifeSciences is trading at a lower price-to-earnings ratio than Prelude Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Maravai LifeSciences	$185.74M	7.46	-$130.77M	-$0.71	N/A
Prelude Therapeutics	$12.14M	28.73	-$99.50M	-$1.00	N/A

Maravai LifeSciences has a beta of 0.72, suggesting that its stock price is 28% less volatile than the broader market. Comparatively, Prelude Therapeutics has a beta of 1, suggesting that its stock price has a similar volatility profile to the broader market.

In the previous week, Prelude Therapeutics had 1 more articles in the media than Maravai LifeSciences. MarketBeat recorded 2 mentions for Prelude Therapeutics and 1 mentions for Maravai LifeSciences. Maravai LifeSciences' average media sentiment score of 1.34 beat Prelude Therapeutics' score of 0.00 indicating that Maravai LifeSciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Maravai LifeSciences	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Prelude Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

50.3% of Maravai LifeSciences shares are held by institutional investors. Comparatively, 79.7% of Prelude Therapeutics shares are held by institutional investors. 2.5% of Maravai LifeSciences shares are held by insiders. Comparatively, 49.2% of Prelude Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Prelude Therapeutics has a net margin of 0.00% compared to Maravai LifeSciences' net margin of -51.07%. Maravai LifeSciences' return on equity of -17.87% beat Prelude Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Maravai LifeSciences	-51.07%	-17.87%	-9.08%
Prelude Therapeutics	N/A	-118.24%	-66.12%

Summary

Prelude Therapeutics beats Maravai LifeSciences on 10 of the 15 factors compared between the two stocks.

How does Prelude Therapeutics compare to Maze Therapeutics?

Maze Therapeutics (NASDAQ:MAZE) and Prelude Therapeutics (NASDAQ:PRLD) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, earnings, analyst recommendations, valuation, institutional ownership, dividends, risk and media sentiment.

Maze Therapeutics currently has a consensus price target of $66.00, indicating a potential upside of 149.91%. Prelude Therapeutics has a consensus price target of $7.67, indicating a potential upside of 75.04%. Given Maze Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Maze Therapeutics is more favorable than Prelude Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Maze Therapeutics	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	3.00
Prelude Therapeutics	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

79.7% of Prelude Therapeutics shares are owned by institutional investors. 5.3% of Maze Therapeutics shares are owned by insiders. Comparatively, 49.2% of Prelude Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Maze Therapeutics has a beta of 2.27, suggesting that its share price is 127% more volatile than the broader market. Comparatively, Prelude Therapeutics has a beta of 1, suggesting that its share price has a similar volatility profile to the broader market.

In the previous week, Maze Therapeutics and Maze Therapeutics both had 2 articles in the media. Maze Therapeutics' average media sentiment score of 1.67 beat Prelude Therapeutics' score of 0.00 indicating that Maze Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Maze Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Prelude Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Maze Therapeutics' return on equity of -36.62% beat Prelude Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Maze Therapeutics	N/A	-36.62%	-31.78%
Prelude Therapeutics	N/A	-118.24%	-66.12%

Prelude Therapeutics has lower revenue, but higher earnings than Maze Therapeutics. Maze Therapeutics is trading at a lower price-to-earnings ratio than Prelude Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Maze Therapeutics	$20M	73.08	-$131.12M	-$2.53	N/A
Prelude Therapeutics	$12.14M	28.73	-$99.50M	-$1.00	N/A

Summary

Maze Therapeutics beats Prelude Therapeutics on 10 of the 15 factors compared between the two stocks.

How does Prelude Therapeutics compare to Phibro Animal Health?

Prelude Therapeutics (NASDAQ:PRLD) and Phibro Animal Health (NASDAQ:PAHC) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, profitability, media sentiment, earnings, analyst recommendations, institutional ownership, risk and valuation.

In the previous week, Phibro Animal Health had 1 more articles in the media than Prelude Therapeutics. MarketBeat recorded 3 mentions for Phibro Animal Health and 2 mentions for Prelude Therapeutics. Phibro Animal Health's average media sentiment score of 0.77 beat Prelude Therapeutics' score of 0.00 indicating that Phibro Animal Health is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Prelude Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Phibro Animal Health	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Prelude Therapeutics has a beta of 1, suggesting that its share price has a similar volatility profile to the broader market.Comparatively, Phibro Animal Health has a beta of 0.46, suggesting that its share price is 54% less volatile than the broader market.

Prelude Therapeutics presently has a consensus target price of $7.67, indicating a potential upside of 75.04%. Phibro Animal Health has a consensus target price of $42.50, indicating a potential upside of 39.21%. Given Prelude Therapeutics' stronger consensus rating and higher probable upside, equities analysts clearly believe Prelude Therapeutics is more favorable than Phibro Animal Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Prelude Therapeutics	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Phibro Animal Health	1 Sell rating(s)	4 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Phibro Animal Health has a net margin of 6.35% compared to Prelude Therapeutics' net margin of 0.00%. Phibro Animal Health's return on equity of 37.14% beat Prelude Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Prelude Therapeutics	N/A	-118.24%	-66.12%
Phibro Animal Health	6.35%	37.14%	8.57%

Phibro Animal Health has higher revenue and earnings than Prelude Therapeutics. Prelude Therapeutics is trading at a lower price-to-earnings ratio than Phibro Animal Health, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Prelude Therapeutics	$12.14M	28.73	-$99.50M	-$1.00	N/A
Phibro Animal Health	$1.30B	0.96	$48.26M	$2.33	13.10

79.7% of Prelude Therapeutics shares are held by institutional investors. Comparatively, 99.3% of Phibro Animal Health shares are held by institutional investors. 49.2% of Prelude Therapeutics shares are held by company insiders. Comparatively, 50.1% of Phibro Animal Health shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

Phibro Animal Health beats Prelude Therapeutics on 11 of the 16 factors compared between the two stocks.

How does Prelude Therapeutics compare to Avalyn Pharma?

Avalyn Pharma (NASDAQ:AVLN) and Prelude Therapeutics (NASDAQ:PRLD) are both small-cap pharmaceutical products companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, risk, media sentiment, analyst recommendations, earnings, valuation, dividends and institutional ownership.

Avalyn Pharma's return on equity of 0.00% beat Prelude Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Avalyn Pharma	N/A	N/A	N/A
Prelude Therapeutics	N/A	-118.24%	-66.12%

79.7% of Prelude Therapeutics shares are held by institutional investors. 49.2% of Prelude Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Avalyn Pharma has higher earnings, but lower revenue than Prelude Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Avalyn Pharma	N/A	N/A	N/A	N/A	N/A
Prelude Therapeutics	$12.14M	28.73	-$99.50M	-$1.00	N/A

In the previous week, Avalyn Pharma had 1 more articles in the media than Prelude Therapeutics. MarketBeat recorded 3 mentions for Avalyn Pharma and 2 mentions for Prelude Therapeutics. Avalyn Pharma's average media sentiment score of 0.00 equaled Prelude Therapeutics'average media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Avalyn Pharma	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Prelude Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Avalyn Pharma presently has a consensus target price of $59.00, indicating a potential upside of 82.72%. Prelude Therapeutics has a consensus target price of $7.67, indicating a potential upside of 75.04%. Given Avalyn Pharma's stronger consensus rating and higher probable upside, analysts clearly believe Avalyn Pharma is more favorable than Prelude Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Avalyn Pharma	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	2 Strong Buy rating(s)	3.20
Prelude Therapeutics	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

Summary

Avalyn Pharma beats Prelude Therapeutics on 6 of the 10 factors compared between the two stocks.

How does Prelude Therapeutics compare to Damora Therapeutics, Inc. Common Stock?

Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) and Prelude Therapeutics (NASDAQ:PRLD) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, dividends, institutional ownership, profitability, earnings, media sentiment, analyst recommendations and risk.

Damora Therapeutics, Inc. Common Stock currently has a consensus price target of $42.43, suggesting a potential upside of 84.95%. Prelude Therapeutics has a consensus price target of $7.67, suggesting a potential upside of 75.04%. Given Damora Therapeutics, Inc. Common Stock's stronger consensus rating and higher probable upside, equities analysts clearly believe Damora Therapeutics, Inc. Common Stock is more favorable than Prelude Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Damora Therapeutics, Inc. Common Stock	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	2 Strong Buy rating(s)	2.91
Prelude Therapeutics	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

14.2% of Damora Therapeutics, Inc. Common Stock shares are owned by institutional investors. Comparatively, 79.7% of Prelude Therapeutics shares are owned by institutional investors. 0.4% of Damora Therapeutics, Inc. Common Stock shares are owned by company insiders. Comparatively, 49.2% of Prelude Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Prelude Therapeutics has higher revenue and earnings than Damora Therapeutics, Inc. Common Stock. Prelude Therapeutics is trading at a lower price-to-earnings ratio than Damora Therapeutics, Inc. Common Stock, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Damora Therapeutics, Inc. Common Stock	N/A	N/A	-$209.84M	-$5.58	N/A
Prelude Therapeutics	$12.14M	28.73	-$99.50M	-$1.00	N/A

In the previous week, Prelude Therapeutics had 2 more articles in the media than Damora Therapeutics, Inc. Common Stock. MarketBeat recorded 2 mentions for Prelude Therapeutics and 0 mentions for Damora Therapeutics, Inc. Common Stock. Damora Therapeutics, Inc. Common Stock's average media sentiment score of 0.00 equaled Prelude Therapeutics'average media sentiment score.

Company	Overall Sentiment
Damora Therapeutics, Inc. Common Stock	Neutral
Prelude Therapeutics	Neutral

Damora Therapeutics, Inc. Common Stock has a beta of 1.46, indicating that its stock price is 46% more volatile than the broader market. Comparatively, Prelude Therapeutics has a beta of 1, indicating that its stock price has a similar volatility profile to the broader market.

Prelude Therapeutics' return on equity of -118.24% beat Damora Therapeutics, Inc. Common Stock's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Damora Therapeutics, Inc. Common Stock	N/A	-428.30%	-114.62%
Prelude Therapeutics	N/A	-118.24%	-66.12%

Summary

Prelude Therapeutics beats Damora Therapeutics, Inc. Common Stock on 8 of the 14 factors compared between the two stocks.

Get Prelude Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PRLD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PRLD vs. The Competition

Export

Metric	Prelude Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$344.07M	$2.97B	$6.45B	$12.39B
Dividend Yield	N/A	1.80%	2.69%	5.83%
P/E Ratio	-4.38	18.43	24.92	23.98
Price / Sales	28.73	327.41	528.23	109.07
Price / Cash	N/A	56.31	44.82	54.51
Price / Book	4.02	4.11	10.79	6.50
Net Income	-$99.50M	$64.45M	$3.56B	$336.88M
7 Day Performance	0.69%	1.41%	1.00%	-0.14%
1 Month Performance	2.58%	1.04%	0.42%	0.77%
1 Year Performance	399.94%	23.88%	29.70%	28.49%

Prelude Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PRLD Prelude Therapeutics	3.639 of 5 stars	$4.38 +1.4%	$7.67 +75.0%	+421.4%	$344.07M	$12.14M	N/A	120	News Coverage
MRVI Maravai LifeSciences	2.5174 of 5 stars	$5.14 +3.5%	$5.50 +7.1%	+154.5%	$1.33B	$185.74M	N/A	610	Positive News
MAZE Maze Therapeutics	2.7819 of 5 stars	$23.69 -2.4%	$66.00 +178.7%	+146.1%	$1.31B	$167.50M	N/A	121	Positive News
PAHC Phibro Animal Health	4.8636 of 5 stars	$31.59 -2.2%	$42.50 +34.6%	+24.8%	$1.28B	$1.30B	13.56	2,475	Upcoming Earnings
AVLN Avalyn Pharma	4.6721 of 5 stars	$28.15 -2.1%	$59.00 +109.6%	N/A	$1.25B	N/A	N/A	51	News Coverage

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PRLD) was last updated on 6/24/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Prelude Therapeutics (PRLD) Competitors

PRLD vs. MRVI, MAZE, PAHC, AVLN, and DMRA

How does Prelude Therapeutics compare to Maravai LifeSciences?

Summary

How does Prelude Therapeutics compare to Maze Therapeutics?

Summary

How does Prelude Therapeutics compare to Phibro Animal Health?

Summary

How does Prelude Therapeutics compare to Avalyn Pharma?

Summary

How does Prelude Therapeutics compare to Damora Therapeutics, Inc. Common Stock?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PRLD vs. The Competition

Prelude Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Prelude Therapeutics (PRLD) Competitors

PRLD vs. MRVI, MAZE, PAHC, AVLN, and DMRA

How does Prelude Therapeutics compare to Maravai LifeSciences?

Do analysts recommend MRVI or PRLD?

Which has stronger valuation & earnings, MRVI or PRLD?

Which has more risk & volatility, MRVI or PRLD?

Does the media prefer MRVI or PRLD?

Do insiders & institutionals have more ownership in MRVI or PRLD?

Is MRVI or PRLD more profitable?

Summary

How does Prelude Therapeutics compare to Maze Therapeutics?

Do analysts recommend MAZE or PRLD?

Do institutionals & insiders believe in MAZE or PRLD?

Which has more risk and volatility, MAZE or PRLD?

Does the media prefer MAZE or PRLD?

Is MAZE or PRLD more profitable?

Which has higher earnings & valuation, MAZE or PRLD?

Summary

How does Prelude Therapeutics compare to Phibro Animal Health?

Does the media favor PRLD or PAHC?

Which has more risk & volatility, PRLD or PAHC?

Do analysts recommend PRLD or PAHC?

Is PRLD or PAHC more profitable?

Which has preferable earnings and valuation, PRLD or PAHC?

Do insiders & institutionals believe in PRLD or PAHC?

Summary

How does Prelude Therapeutics compare to Avalyn Pharma?

Is AVLN or PRLD more profitable?

Do insiders and institutionals hold more shares of AVLN or PRLD?

Which has higher earnings and valuation, AVLN or PRLD?

Does the media favor AVLN or PRLD?

Do analysts prefer AVLN or PRLD?

Summary

How does Prelude Therapeutics compare to Damora Therapeutics, Inc. Common Stock?

Do analysts prefer DMRA or PRLD?

Do insiders & institutionals have more ownership in DMRA or PRLD?

Which has stronger earnings and valuation, DMRA or PRLD?

Does the media prefer DMRA or PRLD?

Which has more risk & volatility, DMRA or PRLD?

Is DMRA or PRLD more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PRLD vs. The Competition

Prelude Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools